title: CD31 immunoreactivity in mesenchymal neoplasms of the skin and subcutis: report of 145 cases and review of putative immunohistologic markers of endothelial differentiation.
abstract: CD31 has recently been reported as a specific marker of endothelial differentiation among non-hematopoietic human neoplasms. In order to address this contention in particular regard to tumors of the skin and subcutis, the authors undertook a comparative study that surveyed 145 mesenchymal lesions. The antibodies used were directed against CD31 (clone JC/70A) and CD34 (clone My10), and these were compared with binding of Ulex europaeus I agglutinin (UEA). Proliferations that were included in the category of vascular tumors included cavernous and capillary hemangiomas (17 cases); lymphangiomas (8); epithelioid ("histiocytoid") hemangiomas (3), papillary endovascular hemangioendothelioma (1), angiosarcoma (7), and Kaposi's sarcoma of the mixed angiomatoid and spindle-cell type (17). CD31-immunoreactivity was observed in 35 of 53 vascular lesions; the neoplastic cells in a single angiosarcoma and the spindle cells in each case of Kaposi's sarcoma (KS) were not labeled. In all of the latter tumors, however, staining for CD31 was identified in the endothelia of angiomatoid areas and non-neoplastic blood vessels. These results compared favorably with those seen with anti-CD34, which decorated 36 of 53 vascular tumors--including 8 of 17 KS cases--and UEA, which bound to the neoplastic cells of 36 lesions. In contrast, all of 92 non-endothelial tumors included in this study (34 nerve sheath tumors [30 benign; 4 malignant]; 39 fibrohistiocytic neoplasms [11 benign; 28 malignant]; 9 smooth muscle tumors [6 benign; 3 malignant]; 7 glomus tumors; and 3 giant cell fibroblastomas) were negative for CD31. UEA labeled 3 non-vascular neoplasms, whereas 38 lesions of that type were CD34-positive.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Lauren V. Ackerman Laboratory of Surgical Pathology, Department of Pathology, Washington University Medical Center, St. Louis, Missouri 63110, USA.
authors.forename: B R
authors.initials: BR
authors.lastname: DeYoung
authors.forename: P E
authors.initials: PE
authors.lastname: Swanson
authors.forename: Z B
authors.initials: ZB
authors.lastname: Argenyi
authors.forename: J H
authors.initials: JH
authors.lastname: Ritter
authors.forename: J F
authors.initials: JF
authors.lastname: Fitzgibbon
authors.forename: D J
authors.initials: DJ
authors.lastname: Stahl
authors.forename: W
authors.initials: W
authors.lastname: Hoover
authors.forename: M R
authors.initials: MR
authors.lastname: Wick
mesh_terms: D018952:Antigens, CD34 / Q000032:analysis; D015214:Antigens, Differentiation, Myelomonocytic / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000276:immunology; D015815:Cell Adhesion Molecules / Q000032:analysis*; D002454:Cell Differentiation / Q000276:immunology; D004730:Endothelium, Vascular / Q000276:immunology* / Q000473:pathology; D006801:Humans; D037102:Lectins / Q000032:analysis; D037121:Plant Lectins; D019408:Platelet Endothelial Cell Adhesion Molecule-1; D012878:Skin Neoplasms / Q000276:immunology* / Q000473:pathology; D019043:Vascular Neoplasms / Q000276:immunology* / Q000473:pathology
chemical_list: D018952:Antigens, CD34; D015214:Antigens, Differentiation, Myelomonocytic; D014408:Biomarkers, Tumor; D015815:Cell Adhesion Molecules; D037102:Lectins; D037121:Plant Lectins; D019408:Platelet Endothelial Cell Adhesion Molecule-1; C036850:Ulex europaeus lectins